Corvus Pharmaceuticals
CRVS
57 hedge funds and large institutions have $44.9M invested in Corvus Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.59% less ownership
Funds ownership: 59.46% → 58.87% (-0.59%)
8% less funds holding
Funds holding: 62 → 57 (-5)
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
33% less capital invested
Capital invested by funds: $66.7M → $44.9M (-$21.8M)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
48% less call options, than puts
Call options by funds: $174K | Put options by funds: $337K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
+$2.39M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$616K |
| 3 |
TI
Telemetry Investments
New York
|
+$173K |
| 4 |
JSC
Jackson Square Capital
San Francisco,
California
|
+$117K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$1.27M |
| 2 |
Two Sigma Investments
New York
|
-$780K |
| 3 |
Two Sigma Advisers
New York
|
-$634K |
| 4 |
VA
VR Adviser
New York
|
-$603K |
| 5 |
Millennium Management
New York
|
-$360K |
CRVS Hedge Fund Activity: Q1 2022 in Review
57 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2022, worth a combined $44.9M — down 33% from $66.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CRVS and 7 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was CHI Advisors, adding an estimated $2.39M. The largest seller was Anson Funds Management, exiting entirely with an estimated $1.27M sold.
- 57 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2022, down from 62 in Q4 2021.
- Funds reported $44.9M of Corvus Pharmaceuticals stock for Q1 2022, down 33% quarter-over-quarter.
- 7 funds opened new Corvus Pharmaceuticals positions in Q1 2022 and 12 closed out, a net change of -5 holders.
- The largest Corvus Pharmaceuticals buyer in Q1 2022 was CHI Advisors, an estimated $2.39M added.
- The largest Corvus Pharmaceuticals seller in Q1 2022 was Anson Funds Management, an estimated $1.27M sold.
Based on aggregated 13F filings for Q1 2022.